Your browser doesn't support javascript.
loading
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.
Nanni, O; Amadori, D; De Censi, A; Rocca, A; Freschi, A; Bologna, A; Gianni, L; Rosetti, F; Amaducci, L; Cavanna, L; Foca, F; Sarti, S; Serra, P; Valmorri, L; Bruzzi, P; Corradengo, D; Gennari, A.
Afiliação
  • Nanni O; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, 47014, Meldola, Italy. oriana.nanni@irst.emr.it.
  • Amadori D; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • De Censi A; Division of Medical Oncology, EO Ospedali Galliera, Genoa, Italy.
  • Rocca A; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Freschi A; Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), Aviano, Italy.
  • Bologna A; Department of Oncology, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy.
  • Gianni L; Department of Medical Oncology, Ospedale Infermi, Rimini, Italy.
  • Rosetti F; Department of Medical Oncology, AULSS, n. 13, Mirano, Italy.
  • Amaducci L; Department of Onco-hematology, Ospedale degli Infermi, Faenza, Italy.
  • Cavanna L; Department of Oncology, AUSL Piacenza, Piacenza, Italy.
  • Foca F; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, 47014, Meldola, Italy.
  • Sarti S; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Serra P; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, 47014, Meldola, Italy.
  • Valmorri L; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, 47014, Meldola, Italy.
  • Bruzzi P; Azienda Ospedaliera Universitaria San Martino IRCCS, Istituto Nazionale per la Ricerca sul Cancro (IST), Genoa, Italy.
  • Corradengo D; Division of Medical Oncology, EO Ospedali Galliera, Genoa, Italy.
  • Gennari A; Division of Oncology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Breast Cancer Res Treat ; 174(2): 433-442, 2019 Apr.
Article em En | MEDLINE | ID: mdl-30536182
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND / 4_TD / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Doxorrubicina / Receptor ErbB-2 / Ciclofosfamida / Metformina Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND / 4_TD / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Doxorrubicina / Receptor ErbB-2 / Ciclofosfamida / Metformina Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2019 Tipo de documento: Article